Trump announces two-year pause on generic drug tariffs, then 100% and 200% rates

President Donald Trump said on July 21, 2026 that imported generic drugs will carry a 0% US tariff for two years starting August 1, 2026, then rise to 100% for one year and to 200% after that ^[1]. He announced the schedule in a post on Truth Social, saying it is meant to reshore generic pharmaceutical production and that the later rate is "a penalty" for companies that do not build plants and equipment in the United States within the time given ^[1][2].

The two-year window with no tariff runs from August 1, 2026 through July 2028. The 100% rate would then apply for one year, followed by 200%, placing the increases in 2028 and 2029 ^[2]. Trump said the administration's separate policy on patented, branded or innovative drugs would remain unchanged ^[1][2]. In April, he signed an executive order imposing 100% tariffs on imported branded pharmaceuticals unless manufacturers agree to government pricing deals or commit to producing their drugs in the US ^[1]. Major drugmakers signed deals with the government last year that exempted billions of dollars of drugs from tariffs ^[1]. Trump has also been pressuring companies through a most-favored-nation pricing policy aimed at lowering US prices to what people pay in other high-income countries ^[1].

Generic drugs account for more than 90% of the medicines sold in the US, according to the Food and Drug Administration ^[1], and roughly 90% of prescriptions dispensed, though they make up only a fraction of prescription drug spending ^[2].

Several practical questions are unanswered. The administration has not released implementation guidance, so how the tariffs would be applied and whether product-specific exemptions would exist has not been disclosed ^[2]. The Association for Accessible Medicines, which represents generic manufacturers, said it is seeking more details and urged the administration to address existing barriers to expanding domestic pharmaceutical manufacturing ^[2]. India, the largest foreign supplier of generic medicines to the US and a major source of finished products and active pharmaceutical ingredients, could be particularly affected ^[2]. About 80% of the active pharmaceutical ingredients used in the US come from China and India ^[2].

Analysts have cautioned that generic manufacturers often operate on narrow margins, and that Medicaid inflation rebates and the 340B program limit their ability to raise prices. Added tariff costs could therefore lead some companies to discontinue certain products rather than pass costs along, which could worsen shortages; older injectable generics, including some cancer drugs, are described as especially exposed ^[2]. Analysts also noted that building and validating new US manufacturing capacity typically takes years longer than the two-year runway the announcement provides ^[2].

Why it matters for patients

Generic medicines are what most Americans actually take: more than nine in ten medicines sold in the US are generics ^[1]. If steep tariffs make some of those products unprofitable, the near-term effect patients could see is not a higher sticker price but a product that is harder to fill, a pattern analysts flagged for low-margin injectables in particular ^[2].

GLP-1 medications currently sold in the US are branded products, and the announcement says the branded-drug policy is unchanged, so this generic schedule does not cover them under the plan as described ^[1][2]. Neither announcement nor the coverage reviewed here names semaglutide, tirzepatide or any specific generic medicine, and how the tariff schedule would apply to any individual product has not been reported ^[1][2].

For people watching for lower-cost generic versions of these drugs, the announcement does not address when any generic GLP-1 might reach the US market or how it would be treated. That has not been disclosed ^[1][2].

What happens next

August 1, 2026: the two-year period with a 0% tariff on imported generics begins ^[1][2].

August 2028: the rate is scheduled to rise to 100% for one year ^[1][2].

August 2029: the rate is scheduled to rise to 200% and stay there ^[1][2].

Implementation guidance, including how the tariff would be applied and whether exemptions would be available, had not been released as of the announcement ^[2].